

EMQN Office Unit 4, Enterprise House, Pencroft Way, Manchester Science Park, Manchester, United Kingdom, M15 6SE Tel: +44 161 757 1591 Email: office@emgn.org

## INDIVIDUAL LABORATORY REPORT (ILR) - Lab 2755

## SCHEME:

OVARIAN and PROSTATE CANCER (v Somatic) [PARPi]

**SEASON: 2022** 

Case 1				
Assessment Category	Score <sup>1</sup>	Comments (& deductions <sup>2</sup> )		
Genotyping	2.00	Correct genotype (0)		
Interpretation	2.00	Insufficient detail regarding variant classification system/evidence used to support classification (0)		
		No statement relating to potential implication of analytical result for family members (0)		
Patient Identifiers and Clerical Accuracy	2.00	Pagination should be used on the report e.g. Page 1 of 1, Page 1 of 2 etc. (0)		
		Failure to indicate an authorising signature (0)		
		Failure to anonymise report (0)		

Case 2				
Assessment Category	Score <sup>1</sup>	Comments (& deductions <sup>2</sup> )		
Genotyping	2.00	Correct genotype (0)		
Interpretation	2.00	All essential interpretive elements provided. No deductions. (0)		
Patient Identifiers and Clerical Accuracy	2.00	Pagination should be used on the report e.g. Page 1 of 1, Page 1 of 2 etc. (0)		
		Failure to indicate an authorising signature (0)		
		Failure to anonymise report (0)		

Case 3				
Assessment Category	Score <sup>1</sup>	Comments (& deductions <sup>2</sup> )		
Genotyping	2.00	Correct genotype (0)		
Interpretation	2.00	Insufficient detail regarding variant classification system/evidence used to support classification (0)		
		No statement relating to potential implication of analytical result for family members (0)		
Patient Identifiers and Clerical Accuracy	2.00	Pagination should be used on the report e.g. Page 1 of 1, Page 1 of 2 etc. (0)		
		Failure to indicate an authorising signature (0)		
		Failure to anonymise report (0)		

Published: 08 June 2023

Page 1 of 2

<sup>&</sup>lt;sup>1</sup> Maximum score is 2.00

<sup>&</sup>lt;sup>2</sup> Deductions from the maximum score

<sup>&</sup>lt;sup>a</sup> Green >= Scheme mean, Orange < Scheme mean, Red Poor performance. NRS no results submitted. WDS withdrew from scheme

<sup>©</sup> Copyright EMQN. No part of this document may be copied, distributed or published in any form without the written permission of the EMQN

General Comments	As per the Scheme Instructions, please anonymise your clinical reports (i.e. remove the name and address of your laboratory) to avoid bias during assessment. Thank for participating in the 2022 BRCA Ovarian and Prostate cancer (Somatic) EQA scheme. We look forward to you joining us in the 2023 scheme- registration to participate is open now (closes February 28th 2023) and available from via the EMQN website.
------------------	--

## SUMMARY OF YOUR PERFORMANCE IN THIS SCHEME

Assessment Category

Genotyping

Interpretation

Patient Identifiers and Clerical Accuracy

## Scheme result (SATISFACTORY or POOR)



Report approved and authorised by Simon Patton (08 June 2023) on behalf of EMQN. Signed:

P SMai bittan

Published: 08 June 2023

© Copyright EMQN. No part of this document may be copied, distributed or published in any form without the written permission of the EMQN

Page 2 of 2

<sup>&</sup>lt;sup>1</sup> Maximum score is 2.00

<sup>&</sup>lt;sup>2</sup> Deductions from the maximum score

Scheme mean, Orange < Scheme mean, Red Poor performance.</li>
NRS no results submitted. WDS withdrew from scheme